Millipore Sigma Vibrant Logo

197333 Bcl-2 Inhibitor VI, ABT-737 - CAS 852808-04-9 - Calbiochem

The Bcl-2 Inhibitor VI, ABT-737, also referenced under CAS 852808-04-9, controls the biological activity of Bcl-2. This small molecule/inhibitor is primarily used for Activators/Inducers applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 4-{4-[(4ʹ-Chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide

View Products on Sigmaaldrich.com
197333
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
197333-10MG
Retrieving availability...
—
Fulfillment and Delivery Delayed Fulfillment and Delivery Delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable nitrophenylsulfonylbenzamide compound that is shown to bind anti-apoptotic Bcl-2 family members Bcl-2, Bcl-XL, and Bcl-w with high affinity (Ki ≤ 1 nM) and serves as a nonpeptidyl alternative to Bad-derived BH3 peptide (Cat. No. 197220) in preventing the binding and inhibition of the pro-apoptotic by the anti-apoptotic Bcl-2 family proteins. ABT-737 is demonstrated to fully reverse the blockage of Myr-Bid-induced cytochrome c release by Bcl-2 in mitochondria preparations from Bcl-2 overexpressing FL5.12 cells and effectively inhibit the growth of numerous cancer cells both in cultures in vitro (IC50 ≤100 nM against H146 and H1963) and in vivo (complete regression of H146 and H1963 in xenograft mice at 100 mg/kg/day, i.p.). Application of ABT-737 is also demonstrated to significantly reduce the disease severity in several murine models of autoimmunity. Also available as a 25 mM solution in DMSO (Cat. No. 197334).
      Catalogue Number197333
      Brand Family Calbiochem®
      Synonyms4-{4-[(4ʹ-Chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide
      References
      ReferencesBardwell, P.D., et al. 2009. J. Immunol. 182, 7482.
      Oltersdorf, T., et al. 2005. Nature 435, 677.
      Product Information
      CAS number852808-04-9
      FormYellow solid
      Hill FormulaC₄₂H₄₅ClN₆O₅S₂
      Chemical formulaC₄₂H₄₅ClN₆O₅S₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      197333-10MG 04055977206104

      Documentation

      Bcl-2 Inhibitor VI, ABT-737 - CAS 852808-04-9 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Bcl-2 Inhibitor VI, ABT-737 - CAS 852808-04-9 - Calbiochem Certificates of Analysis

      TitleLot Number
      197333

      References

      Reference overview
      Bardwell, P.D., et al. 2009. J. Immunol. 182, 7482.
      Oltersdorf, T., et al. 2005. Nature 435, 677.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-August-2010 RFH
      Synonyms4-{4-[(4ʹ-Chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide
      DescriptionA cell-permeable nitrophenylsulfonylbenzamide compound that is shown to bind anti-apoptotic Bcl-2 family members Bcl-2, Bcl-XL, and Bcl-w with high affinity (Ki ≤1 nM) and serves as a nonpeptidyl alternative to Bad-derived BH3 peptide (Cat. No. 197220) in preventing the binding and inhibition of the pro-apoptotic by the anti-apoptotic Bcl-2 family proteins. ABT-737 is demonstrated to fully reverse the blockage of Myr-Bid-induced cytochrome c release by Bcl-2 in mitochondria preparations from Bcl-2 overexpressing FL5.12 cells and effectively inhibit the growth of numerous cancer cells both in cultures in vitro (IC50 ≤100 nM against H146 and H1963) and in vivo (complete regression of H146 and H1963 in xenograft mice at 100 mg/kg/day, i.p.). Application of ABT-737 is also demonstrated to significantly reduce the disease severity in several murine models of autoimmunity.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number852808-04-9
      Chemical formulaC₄₂H₄₅ClN₆O₅S₂
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesBardwell, P.D., et al. 2009. J. Immunol. 182, 7482.
      Oltersdorf, T., et al. 2005. Nature 435, 677.